文献速递重症综合管理与镇静镇痛

危重症早期持续植物乳杆菌益生菌治疗:危重症肠道菌群恢复随机安慰剂对照试验(ROCIT)

Early and sustained Lactobacillus plantarum probiotic therapy in critical illness: the randomised, placebo-controlled, restoration of gut microflora in critical illness trial (ROCIT).
PubMed 文献 · Intensive Care Med · 2021-02-10
一句话结论成人ICU患者早期持续使用植物乳杆菌299v益生菌安全,但未改善至第60天存活且出院天数或院内感染率。

这项多中心、平行组、安慰剂对照随机临床试验纳入ICU入院48小时内且预期需继续ICU治疗的成人患者,比较植物乳杆菌299v与安慰剂(入组后立即给药并持续60天)对至第60天存活且出院天数(DAOH60)的影响。益生菌组(n=110)DAOH60中位数49.5天(IQR 37.0-53.0),安慰剂组(n=108)49.0天(IQR 43.8-53.0),组间差异0.0天(95%CI -6.10至7.1,P=0.55)。院内感染益生菌组8例(7.3%)、安慰剂组5例(4.6%),OR 1.62(95%CI 0.51-5.10),P=0.57。无严重不良事件或益生菌相关不良事件。作者认为早期持续非靶向给予植物乳杆菌299v安全,但与患者结局改善无关。

要点

  • 成人ICU患者早期持续植物乳杆菌299v治疗未增加至第60天存活且出院天数:益生菌组49.5天 vs 安慰剂组49.0天,组间差异0.0天(95%CI -6.10至7.1,P=0.55)。
  • 院内感染益生菌组8例(7.3%) vs 安慰剂组5例(4.6%),OR 1.62(95%CI 0.51-5.10),P=0.57,未达统计学显著。
  • 无严重不良事件或益生菌相关不良事件报告。
  • 作者结论:早期持续非靶向给予植物乳杆菌299v对成人ICU患者安全,但与患者结局改善无关。

适用人群与场景

  • 成人患者,ICU入院48小时内且预期需在入组次日之后继续接受ICU治疗。

处置流程与药物剂量

  • 植物乳杆菌299v或安慰剂于入组后立即给药,并持续60天。

研究设计与关键结果

  • 多中心、平行组、安慰剂对照、随机临床试验;益生菌组n=110,安慰剂组n=108。
  • 主要终点至第60天存活且出院天数(DAOH60)中位数:益生菌组49.5天(IQR 37.0-53.0) vs 安慰剂组49.0天(IQR 43.8-53.0),组间差异0.0天(95%CI -6.10至7.1,P=0.55)。
  • 院内感染:益生菌组8例(7.3%) vs 安慰剂组5例(4.6%),OR 1.62(95%CI 0.51-5.10),P=0.57。
  • 无严重不良事件或益生菌相关不良事件。

证据类型、等级与局限

  • 随机、安慰剂对照临床试验;局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对成人ICU患者早期持续非靶向给予植物乳杆菌299v是安全的,但与患者结局改善无关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: In adults requiring treatment in an intensive care unit, probiotic therapy using Lactobacillus plantarum 299v may reduce nosocomial infection. The aim of this study was to determine whether early and sustained L. plantarum 299v therapy administered to adult ICU patients increased days alive and at home.

METHODS: A multicentre, parallel group, placebo-controlled, randomised clinical trial was conducted. Adult patients within 48 h of intensive care admission and expected to require intensive care beyond the day after recruitment were eligible to participate. L plantarum 299v or placebo were administered immediately after enrolment and continued for 60 days. The primary outcome was days alive and out of hospital to Day 60 (DAOH60). Secondary outcomes included nosocomial infections.

RESULTS: The median [interquartile range (IQR)] number of DAOH60 in the probiotic (n = 110) and placebo group (n = 108) was 49.5 (IQR 37.0-53.0) and 49.0 (IQR 43.8-53.0) respectively, between-group difference of 0.0 [95% confidence interval (CI) - 6.10 to 7.1, P = 0.55]. Nosocomial infection occurred in 8 (7.3%) and 5 (4.6%) of the probiotic and placebo group participants, respectively, odds ratio 1.62 (95% CI 0.51-5.10), P = 0.57. There were no serious, or probiotic-associated adverse events.

CONCLUSION: Early and sustained untargeted administration of probiotic therapy with Lactobacillus plantarum 299v to adult patients admitted to the ICU is safe, but not associated with improved patient outcomes.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Litton E, Anstey M, Broadhurst D, et al. Early and sustained Lactobacillus plantarum probiotic therapy in critical illness: the randomised, placebo-controlled, restoration of gut microflora in critical illness trial (ROCIT). Intensive Care Med. 2021. PMID: 33566129. doi:10.1007/s00134-020-06322-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。